[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351621-105":59,"doc-detail-351621-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","outcomes-of-pulmonary-metastasectomy-in-urological-cancer-insights-from-a-retrospective-cohort","Outcomes of pulmonary metastasectomy in urological cancer - insights from a retrospective cohort","","Pulmonary metastasectomy is an established option for selected patients with metastatic disease, yet its value in urological malignancies is insufficiently defined. This retrospective single-center study evaluated 18 patients undergoing pulmonary resection for suspected metastases from urological cancers (2014–2023), with 11 patients in a renal cell carcinoma (RCC) subgroup. Confirmed metastases occurred in 14 patients. Median disease-free interval was 25 months and median overall survival after resection was 113 months. In RCC, 10-year survival exceeded 50% despite 66.7% recurrence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/outcomes-of-pulmonary-metastasectomy-in-urological-cancer-insights-from-a-retrospective-cohort/351621/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/outcomes-of-pulmonary-metastasectomy-in-urological-cancer-insights-from-a-retrospective-cohort/351621.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population and study design were included?","Question",{"text":112,"@type":113},"The study was a retrospective, single-institution review of 18 patients who underwent pulmonary resection for suspected metastases from urological malignancies between 2014 and 2023.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were pulmonary lesions classified in the cohort?",{"text":117,"@type":113},"Pulmonary lesions were confirmed as metastatic in 14 patients and as showing inflammatory changes in four.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were reported overall and for the RCC subgroup?",{"text":121,"@type":113},"Overall, the median disease-free interval was 25 months and median overall survival after resection was 113 months. In the RCC subgroup, 10-year survival was over 50% despite a 66.7% recurrence rate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351621,1790466930,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Submitted 4 December 2025 Accepted 13 March 2026 Published 4 May 2026  \nCorresponding author Ryusei Yoshino, [ryusei.0628.ppp@gmail.com](ryusei.0628.ppp@gmail.com)  \nAcademic editor Faiza Farhan  \nAdditional Information and Declarations can be found on page 14  \nDOI 10.7717/peerj.21171  \n Copyright 2026 Yoshino et al.  \nDistributed under  \nCreative Commons CC-BY 4.0  \nOPEN ACCESS  \nOutcomes of pulmonary metastasectomyin urological cancer: insights from a retrospective cohort  \nRyusei Yoshino, Kengo Takahashi, Nozomi Hatanaka, Akane Ito, Nanami Ujiie, Shunsuke Yasuda and Masahiro Kitada  \nThoracic Surgery, Asahikawa Medical University, Asahikawa, Japan  \nABSTRACT  \nPulmonary metastasectomy has been established as a treatment option for select patients with metastatic disease. However, its role in urological malignancies remains underexplored. This study aimed to evaluate the clinical outcomes of pulmonary metastasectomy in patients with urological cancers, with a focus on renal cell carcinoma (RCC) . We retrospectively reviewed 18 patients who underwent pulmonary resection for suspected metastases from urological malignancies at a single institution between 2014 and 2023. A subgroup analysis of 11 patients with RCC was conducted. The cohort included 13 patients with kidney cancer, four with testicular tumors, and one with prostate cancer. Pulmonary lesions were confirmed to be metastatic in 14 patients and inflammatory changes in four. The median disease-free interval was 25 months and the median overall survival after pulmonary resection was 113 months. In the RCC subgroup, the 10-year survival rate exceeded 50%, despite a 66.7% recurrence rate. No significant prognostic factors were identified, although favorable trends were observed for younger age, solitary metastases, and absence of vascular invasion. Inurological malignancies, particularly renal cell carcinoma, pulmonary metastasectomy was associated with prolonged survival in carefully selected patients. Surgical resection may serve both therapeutic and diagnostic purposes, supporting its role within a multidisciplinary treatment strategy.  \nSubjects Oncology, Surgery and Surgical Specialties, Urology  \nKeywords Pulmonary metastasectomy, Urological malignancies, Renal cell carcinoma, Oligometastatic disease, Surgical outcome  \nINTRODUCTION  \nPulmonary metastases represent a common clinical scenario in the course of various malignancies, and surgical resection􀀖pulmonary metastasectomy􀀖has been performed in select patients for decades to achieve disease control or a potential cure (Raveglia et al., 2021; Meacci et al., 2017) . While most literature on metastasectomy focuses on sarcomas, colorectal cancer, and renal cell carcinoma (RCC), pulmonary metastases from urological malignancies remain relatively under-investigated as a distinct clinical entity. A multi-institutional study of urogenital tumors identified 22 of 126 metastasectomy cases as originating from urological cancers, highlighting the rarity and diagnostic challenges of these lesions (Ceylan, Bat􀀙 han & Kaya, 2023) .  \nHow to cite this article Yoshino R, Takahashi K, Hatanaka N, Ito A, Ujiie N, Yasuda S, Kitada M. 2026. Outcomes of pulmonary metastasectomy in urological cancer: insights from a retrospective cohort. PeerJ 14:e21171 [http://doi.org/10.7717/peerj.21171](http://doi.org/10.7717/peerj.21171)  \nRCC is known for its unpredictable clinical course, with oligometastatic pulmonary disease occurring in a notable subset. Testicular germ cell tumors are highly chemosensitive; however, residual pulmonary nodules frequently require surgical resection after first-line chemotherapy (Caso et al., 2021) . In contrast, pulmonary metastases from urothelial carcinoma (UC) or prostate cancer remain rare; however, recent data suggest that UC metastasectomy may prolong survival in select patients ( Yamauchi et al., 2024) .  \nAdvances in systemic therapies, including immune checkpoint inhibitors (ICIs), vascular endothel","cbCaicGOeWeD9TFg","https://ap.wps.com/l/cbCaicGOeWeD9TFg","pdf",260487,17,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Study design and patient selection","[{\"question\":\"What patient population and study design were included?\",\"answer\":\"The study was a retrospective, single-institution review of 18 patients who underwent pulmonary resection for suspected metastases from urological malignancies between 2014 and 2023.\"},{\"question\":\"How were pulmonary lesions classified in the cohort?\",\"answer\":\"Pulmonary lesions were confirmed as metastatic in 14 patients and as showing inflammatory changes in four.\"},{\"question\":\"What outcomes were reported overall and for the RCC subgroup?\",\"answer\":\"Overall, the median disease-free interval was 25 months and median overall survival after resection was 113 months. In the RCC subgroup, 10-year survival was over 50% despite a 66.7% recurrence rate.\"}]","Outcomes of pulmonary metastasectomy in urological cancer - insights from a retrospective cohort | PDF",1790094977,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0496f9fd36b757ec54e47adb01dfbeb3.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa19232d8ce027dceae88ff4de94e083.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06cc73405cd524f7ecc6001bcb77db0f.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/272601aed52e805bc7c969d48c145bfc.webp",980,1268]